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Abstract
Medical studies for chronic disease are often interested in the relations between
longitudinal risk factor profiles and the risk of disease outcomes in later life. These
profiles may be subject to intermediate structural changes due to treatment or en-
vironmental influences. Analysis of such studies may be handled by the joint model
framework. However, current joint modeling does not consider either structural
changes in the residual variability of the risk profile or the influence of subject-specific
residual variability of the risk profile on the time-to-event outcome. In the present
paper, we extend the joint model framework to address these two heterogeneous
intra-individual variabilities. A Bayesian approach is used to estimate the unknown
parameters and simulation studies are conducted to investigate the performance of
the method. The proposed joint model is applied to data from the Framingham
Heart Study to investigate the influence of anti-hypertensive medications on the sys-
tolic blood pressure variability together with the effect of such medication use on the
risk of developing cardiovascular disease. We show that anti-hypertensive medication
use is associated with elevated systolic blood pressure variability and such increased
systolic pressure variability is associated with an increased risk of developing cardio-
vascular disease.
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1 Introduction
Medical studies of risk of chronic diseases such as cancer, human immunodeficiency virus
(HIV), and cardiovascular diseases (CVD), frequently involve studying longitudinal mea-
surements of certain risk factors in relation to individuals’ later life risk of disease out-
comes. The trajectories or the longitudinal profiles of the risk factors, which describe the
progression of the risk factor variables over time, may play an important role in preven-
tive healthcare. Indeed, the risk factors are commonly monitored to make decision about
timely interventions and to help predict later life diseases. Thus, in observational stud-
ies, the longitudinal profiles of risk factors are subject typically to intermediate structural
changes caused by factors such as treatment interventions, behavioral adaptations, or en-
vironmental changes. Disruptions of the longitudinal profile typically may have an effect
on the time-to-event outcome. Furthermore, structural changes in the longitudinal profile
of risk factors may include immediate changes in the values for the risk factor, changes in
growth rate of the risk profile trajectory, and changes in the variability of the risk factor.
All these changes may happen simultaneously and they may have distinctive effects on the
disease outcomes. These phenomena are commonly observed in life course epidemiology
(Ben-Shlomo and Kuh, 2002; Kuh and others , 2002; Kuh and Shlomo, 2004).
To address research questions about the association of the longitudinal profiles of risk
factors and the time to outcome events of interest, statistical analyses are often conducted
with some form of joint models. These joint models often assume either that the existence of
a set of low-dimensional unobserved time-independent variables that vary across individuals
and operate underneath both the longitudinal profile and the survival time (Wulfsohn and
Tsiatis, 1997), or that the risk of occurrence of an outcome event is directly associated
with the latent (functions of) smooth longitudinal profile (Rizopoulos, 2012; Papageorgiou
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and others , 2019). Joint models focus on how the levels of the smooth profiles of risk
factors are associated with prognosis (Tsiatis and Davidian, 2004). Recent advances in
joint models extended single longitudinal risk factor profiles to multiple risk factor profiles
with possible extension to different risk factor types (Larsen, 2004; Chi and Ibrahim, 2006;
Andrinopoulou and others , 2014; Musoro and others , 2015; Proust-Lima and others , 2014).
Nevertheless, the main associations between the longitudinal risk factor profiles and the
time-to-event outcomes still closely follow the two approaches described above. Whilst,
relations between other features of the longitudinal profiles, such as their intra-individual
variability, and the time-to-event outcome is less frequently investigated.
The present investigation is motivated by data from the Framingham Heart Study (Daw-
ber and others , 1951), an observational cohort study across multiple generations aimed to
identify the common factors or characteristics that contribute to CVD. In the past, the
Framingham Heart Study data have been used to investigate the associations between var-
ious blood pressure components, including systolic blood pressure (SBP), diastolic blood
pressure (DBP), and pulse pressure (PP), with the risk of developing CVD (see for exam-
ple Levy, 1999; Kannel, 1996; Franklin and others , 2014, 2015; Nayor and others , 2018).
In addition, the Framingham Heart Study data have been used to study the hemodynamic
patterns of age-related changes in blood pressure (Kannel and others , 1971; Franklin and
others , 1999, 2009). Hathaway and D’Agostino (1993) reported a significant association
between variance of SBP and subsequent coronary heart disease among a group of 516
women in the Framingham Heart Study. Their approach resembled a two-step joint model
(an earlier version of the current joint model framework). Summary statistics based on
regression of the SBP on age and the original observed repeated measurements of SBP
were considered as independent predictors in a logistic regression model for coronary heart
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disease. This two-step approach, however, is known to produce biased estimates in the
joint model literature (Tsiatis and Davidian, 2004; Rizopoulos, 2012).
It has been established that increased long-term SBP variability is associated with an
increased risk of CVD events and mortality (Stevens and others , 2016; Sponholtz and
others , 2019). However, currently available methods for evaluating SBP variability are
diverse - they include standard deviation, coefficient of variation, average real variability
(sum of absolute difference between two consecutive SBPs) (Mena and others , 2005), and
variability independent of mean (Rothwell and others , 2010). Several methodological issues
have been raised related to these analysis and our understanding of SBP variability (Stevens
and others , 2016). First, analysis of variability need to take into account the correlation
between high mean blood pressure and high variability. Second, variabilities based on the
repeated measurements during follow-up are frequently used in studies as a baseline risk
factor, which potentially introduces immortal-time bias and other related problems that
joint model attempts to address.
In the present investigation, we extend the commonly used joint model (Rizopoulos,
2012) for a longitudinal profile with heterogeneous intra-individual variabilities and relate
the risk of developing chronic disease to the intra-individual variability in combination with
disruptive risk profiles due to treatment interventions. A partial likelihood of the aforemen-
tioned statistical model is proposed that is proportional to the complete likelihood where
the initiation of treatment of a risk factor is assumed to be associated with the observed
value of the longitudinal profile of the risk factor but does not share parameters with the
longitudinal and survival models. A Monte Carlo Markov Chain (MCMC) algorithm was
used to estimate the parameters in the longitudinal and the survival models.
The rest of this paper is organized as follow. In Section 3, we propose a joint model for
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the longitudinal profile, the treatment initiation for a given risk factor, and the survival
outcome of interest. Furthermore, we construct the likelihood function for the proposed
model, which leads to the partial likelihood function for the longitudinal and survival
outcome only. We provide the prior distributions for the parameters of interests and the
posterior sampling scheme in Section 4. In Section 5, a simulation study is described.
In Section 6, the proposed joint model is fitted to the Framingham Heart Study data
and the effect of the SBP variability on the risk of developing CVD and the effect of the
anti-hypertensive medication on the SBP variability are estimated. Discussion follows in
Section 7.
2 Motivating example
Data of the first generation cohort of the Framingham Heart Study is considered in this
investigation. The Framingham Heart Study started in 1948 with its initial enrollment of an
original cohort of 5209 men and women between the ages of 30 and 62 years from the town
of Framingham, Massachusetts, United States of America. The collected data consisted
of extensive medical history, physical examinations performed independently by at least
two physicians, chest X-ray, electrocardiogram, and blood and urine samples. We focus
on SBP, measured every two years during follow-up together with the status on whether
anti-hypertensive medications were administrated since the last examination. Furthermore,
CVD status at each examinations was also recorded. The interest is to investigate (1) the
effect of the anti-hypertensive medications on the SBP, (2) its related risk of developing
CVD, and (3) the effect of SBP variability on the risk of developing CVD.
Preliminary analysis of the Framingham Heart Study data was conducted by fitting the
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subject-specific growth model (2) described later in Section 3 without heteroscedasticity
(i.e., intra-individual variance of the SBP σ2ij = σ
2
0) to the data. Results indicate that the
residual variance across individuals for SBP before treatment is heteroscedastic. Figure 1
displays that the SBP variability before treatment differs between two individuals. In
addition, it can be shown that the estimated residual variance for SBP before treatment
does not follow a chi-square distribution. Under homoscedasticity, it was expected that the
sum of squares of the qi residuals (qi − 1)s20i for individual i before treatment, divided by
the variance of all residuals before treatment σ20, has a chi-square distribution with qi − 1
degrees of freedom:
1
σ20
(qi − 1)s20i ∼ χ2qi−1.
This distributional assumption remains approximately true for large numbers of partici-
pants when σ20 is replaced by its estimate σˆ
2
0 over all residuals before treatment. However,
Figure 2 demonstrates a clear violation of normality for the transformation Φ−1
(
χ2qi−1((qi − 1)s20i/σˆ20)
)
(Anderson-Darling A2 = 16.11, p < 0.005). Clearly, the variability in the variances exceeds
the variance of the chi-square distribution. Another important observation is that the intra-
individual variability changes after treatment within patients. The residual variance seems
to increase which is depicted in Figure 3 where the histogram of the residual variances for
SBP before and after treatment are depicted.
3 Methods
3.1 Treatment and longitudinal profile
Let Y ′i = (Yi1, . . . , Yi,mi) denote the vector of repeated measurements of the longitudi-
nal risk factor profile for individual i (i = 1, . . . , N) at measurement occasions tij with
7
Figure 1: Systolic blood pressure of two individuals fitted with a homoskedastic subject-
specific model. Dots: Original observations; Lines: Conditional mean profile: µˆij; Shaded
area: 95% CI: µˆij ± 1.96SD(yij − µˆij) (SD: standard deviation before and after treatment)
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Figure 2: Normality plot of the transformed residual variances of individuals before treat-
ment
9
Figure 3: Residual variances of individuals on systolic blood pressure before and after
treatment.
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j = 0, 1, . . . ,mi and ti0 = 0 indicating the baseline, and Z
′
i = (Zi1, . . . , Zimi) the corre-
sponding treatment indicator with Zij = 1 meaning treatment is administrated at the jth
measurement occasion, and 0 otherwise. Assuming that treatment is administrated based
on the observed value of the longitudinal profile, as well as the previous treatment condition
of the individual, we may assume that
P (Zij = 1|Yij = yij;Zi,j−1) = Zi,j−1 + (1− Zi,j−1)Φ(α0 + α1yij), (1)
where Φ is the standard normal cumulative distribution function and α = (α0, α1)
′ are
unknown parameters related to the treatment process. Implicitly, we assume that Yij
precedes Zij, namely the observed value of Yij is used to determine treatment adminis-
tration at measurement j. In this treatment-model, the only factors that determines the
initiation of treatment is the most recent measurement of the observed longitudinal pro-
file and previous treatment condition. This may be a simplification of a real-life decision
processes, since other measured factors could contribute to the treatment decision, but
our treatment-model can be extended to include other factors. It should be noted that,
when an individual is already under treatment Zij−1 = 1, treatment will not stop, namely
P (Zij = 1|Yij, Zij−1 = 1) = 1 as implied by the formulation of model (1). This may be
realistic when medication is used for chronic conditions. Thus we will not consider the
possibility of treatment cessation in the present investigation.
For the longitudinal profile, a subject-specific linear growth model is specified as
P (Yij ≤ yij|ri, Zij−1) = Φ
(
yij−µij
σij
)
,
µij = b0i + b1itij + Zij−1 {b2i + b3i(tij − si)} ,
σ2ij = σ
2
0 exp(νZij−1 + ci),
(2)
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where the random term ri = (b0i, b1i, b2i, b3i, ci)
′ is assumed to follow a multivariate normal
distribution ri ∼ N (θ,Σ) with θ = (β0, β1, β2, β3, 0)′, σ20 the mean residual variance before
treatment over all individuals, tij is the time point of the jth measurement occasion for
individual i, si = tiji with ji = inf{j : Zij − Zij−1 = 1} is the time when treatment is
first initiated (si is considered equal to ti,mi if no treatment is administrated to individual
i during the follow-up), and σ2ij is the intra-individual variance that depends on the latent
variable ci and treatment indicator Zij−1 with a multiplicative treatment effect equal to
exp(ν) on the variance. The conditional mean µij of the longitudinal profile is formulated
such that treatment would have effects on both the absolute value and the rate of changes
of the longitudinal profile. The four latent variables b1i, b2i, b3i, b4i represents the subject-
specific baseline profile, growth rate without treatment,immediate treatment effect on the
profile and change in growth rate after treatment, respectively. Furthermore, treatment is
assumed to have a multiplicative effect on the variability of the profile while the between-
individual variability of the variance is captured by the latent variable ci. The covariance
matrix Σ allows the latent variable ci to be correlated with the latent variables b1i, b2i, b3i, b4i
in the conditional mean. This provides opportunities to investigate the correlation between
the variabilities and different aspects of the longitudinal profile and understanding of how
the individual variability is related to the longitudinal profile before and after treatment.
3.2 Survival time and event
Let Ti = min(T
∗
i , Ci) be the observed survival time for individual i taking the value of
the true survival time T ∗i if the event is observed and otherwise taking the value of the
censoring time Ci. The hazard rate λi(t) is specified as
λi(t) = λ0(t) exp
(
γ0µi(t) + γ1 log σ
2
i (t)
)
, (3)
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where µi(t) = b0i + b1it+ Zij−1{b2i + b3i(t− si)}, and σ2i (t) = σ20 exp(νZij−1 + ci) with {j :
tij−1 < t ≤ tij}, and γ0, γ1 their corresponding effects on the hazard function, respectively,
and λ0(t) the baseline hazard function of a parametric survival distribution such as the
Weibull distribution. In addition, the event indicator is denoted by Di = 1({T ∗i ≤ Ci}).
The survival model implies that the hazard ratio between two individuals i and j with the
same conditional mean profile but different variabilities would be equal to
λi(t)
λj(t)
=
exp(γ1 log σ
2
i )
exp(γ1 log σ2j )
= exp
{
γ1 log
(
σ2i
σ2j
)}
.
Furthermore, no direct treatment effect is specified in the survival model. This reflects
the modeling assumption that the effect of the treatment is completely being mediated by
the structural changes in the longitudinal profile. Alternatively, we can also incorporate a
direct effect of the treatment into the hazard function.
3.3 The likelihood function
The joint distribution of the longitudinal pair (Yi,Zi) and the survival pair (Ti, Di) for
individual i is
f(Yi,Zi, Ti, Di) =
∫
R5
f(Yi,Zi, Ti, Di|ri)f(ri)dri.
We will further assume, that conditional on the latent variables ri, the survival outcome
is independent of the longitudinal profile. As a consequence, the joint distribution can be
expressed as
f(Yi,Zi, Ti, Di) = f(Zij|Yi,j−1, Zi,j−1)
∫
f(Yi1|ri)
mi∏
j=2
f(Yij|Zi,j−1, ri)
× f(Ti, Di|ri)f(ri)dri
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Since the treatment model (1) does not depend on the latent variables ri, the term
f(Zij|Yi,j−1, Zi,j−1) moved outside the integral. This remains true when we would en-
hance it with additional risk factors, earlier values from the longitudinal data or include
the treatment indicator in the hazard function. It should be noted that it is more realis-
tic to have the treatment model depend on Yij instead of ri since treatment interventions
would be based on the observations rather than the expected observations. If we further
assume that the treatment model does not share any common unknown parameters with
the longitudinal and survival models (ignorability), the unknown parameters in the treat-
ment model can be ignored. Therefore, to obtain the estimates of the unknown parameters
in the longitudinal and survival models, the following partial likelihood for individual i is
considered:
Lpartiali =
∫
f(Yi1|ri)
mi∏
j=2
f(Yij|Zi,j−1, ri)f(Ti, Di|ri)f(ri)dri
=
∫ mi∏
j=1
φ
(
yij − µij
σij
)
φ
(√
(ri − θ)′Σ−1(ri − θ)
)
× λDii (Ti) exp
(
−
∫ Ti
0
λi(s)ds
)
dri,
where φ(·) is the standard normal density function. Furthermore, the integration of the
hazard function with respect to time in the survival model is approximated by
∫ Ti
0
λi(s)ds ≈
mi∑
j=1
∫ tij
ti,j−1
λi(s)ds+
∫ Ti
ti,mi
λi(s)ds
=
mi∑
j=1
(Λ0(tij)− Λ0(ti,j−1)) exp(γ0µi,j−1 + γ1 log σ2i,j−1)
+ (Λ0(Ti)− Λ0(ti,mi)) exp(γ0µi,mi + γ1 log σ2i,mi)
14
using an event history formulation similar to Henderson and others (2000), where Λ0 is the
cumulative baseline hazard function. We implicitly assumed a piece-wise constant function
for both µij and σij within the interval [tij, ti,j+1) and that is left-continuous with respect
to time.
Unfortunately, direct maximization of the partial likelihood may yield biased estimates
for γ1 due to the effect of the variability in the hazard function. The reason is that the
maximum likelihood estimator tends to underestimate the variance components of the
longitudinal profile in small sample cases due to the failure to account for a reduction in
degrees of freedom associated with fixed effects parameters. The underestimated variance
component of the latent variable ci will consequently lead to a underestimated σ
2
ij which in
turn will cause overestimation of γ1 in the survival model. Therefore, a restricted maximum
likelihood (REML) estimator is needed to transform the partial likelihood such that the
distribution of the error construct is unrelated to those parameters. However, finding a
transformation of the data consisted of both longitudinal profile and survival outcome is
not trivial. One alternative can be derived using a Bayesian formulation by introducing
a flat prior for the fixed effect parameters. This approach was considered by Harville
(1974, 1976) and Dempster and others (1981) and has been shown to coincide with the
REML estimates. Furthermore, the empirical Bayes estimates of the latent variables are
the estimated means of the posterior distributions (Laird and Ware, 1982). Therefore,
we take a Bayesian approach to estimate the parameters of interests by introducing prior
distributions to the fixed effect parameters.
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4 Sampling posterior distribution via MCMC
Unbounded uniform priors on (−∞,∞) are specified for all fixed effects parameters β0, β1,
β2, β3, ν, γ0, γ1 independent of each other. A truncated half-normal prior was assigned to
σ0. For the parameters involved in the baseline survival distribution (e.g., Weibull parame-
ters), bounded uniform priors are specified. For instance, for the shape and scale parameters
of the Weibull baseline, we considered a [0, U ]-uniform distribution with U >> Uˆ . Here Uˆ
is the estimated parameter value obtained from a standalone fit of the survival model to
the data. For the covariance matrix Σ, we decompose the prior into a scale and a corre-
lation matrix. Specifically, Σ = diag(τ ) Ω diag(τ ), where the vector τ is a vector of scale
coefficients τk =
√
Σk,k of the (k, k)-diagonal of the covariance matrix, Ω the correlation
matrix with its (p, q) entry Ωp,q = (τpτq)
−1Σp,q. A half-Cauchy distribution C+(0, 2.5) is
specified as the prior for τk, and a LKJ correlation distribution (Lewandowski and others ,
2009) is specified for the correlation matrix Ω (Gelman and others , 2013). The primary
motivation for adopting this weakly-informative prior distribution for τk is to constrain the
intra-individual variance before and after treatment away from very large values in case of
insufficient number of follow-up measurements for some individuals (Gelman and others ,
2006). Further reparametrization of τ and Cholesky factorization of the correlation ma-
trix Ω are used only for computational purposes. Posterior samples are generated using
the No U-Turn Sampler (NUTS), an extension to the Hamiltonian Monte Carlo algorithm
(Hoffman and Gelman, 2014).
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5 Simulations
5.1 Data generation
The simulated data is generated according to the three models described in Section 3. For
each individual, the latent variables ri were drawn from a multivariate normal distribution
N (θ,Σ), where θ = (12, 0.1,−0.3,−0.05, 0)′ and
Σ =

4 −0.02 −0.2 −0.05 0.6
−0.02 0.005 −0.015 0.005 0.01
−0.2 −0.015 1 −0.02 −0.1
−0.05 0.005 −0.02 0.015 −0.025
0.6 0.01 −0.1 −0.025 0.3

.
Furthermore, the jth (j = 1, . . . ,mi = 10) measurement time was generated by drawing
uniformly from the interval [j, j+1). Afterwards, the longitudinal risk factor profile and the
treatment (of the risk factor) indicator Yij, Zij were generated recursively according to Zi,j−1
and Yi,j−1 following the longitudinal and the treatment model, respectively. Treatment at
baseline Zi0 is taken to be 0 for all individuals. For the treatment model, the corresponding
parameters were specified to be α0 = −5 and α1 = 0.05 such that 40% of the individuals
received treatment during the course of the follow-up. While, in the longitudinal profile,
σ0 = 2, and ν = 0.5. For the survival model, a Weibull baseline hazard function
λ0(t) =
k
ξ
(
t
ξ
)k−1
was specified with the scale parameter ξ = 150 and shape parameter k = 1.5. Survival time
Ti was determined using the previously generated conditional mean of the longitudinal pro-
file and the intra-individual variability according to the survival model. The corresponding
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coefficients were set to γ0 = 0.05 and γ1 = 0.2. Since both the conditional mean of the
longitudinal profile and the intra-individual variability were time-dependent covariates, a
simulation algorithm proposed by Prikken et al. (Prikken and others , 2019) for generating
survival time according to the Cox’s regression model with time-dependent covariates was
used. After the survival time was determined, data related to observations at periods later
than the survival time was discarded. In case the simulated survival time is larger than
the last measurement time of the longitudinal profile, the individual was considered to be
censored at the last time point of the longitudinal data.
In total 500 simulation runs were performed with each simulation containing 100 indi-
viduals. The proposed model was fitted to each simulated data set using the Stan Bayesian
statistical analysis and computation platform (Carpenter and others , 2017). For each sim-
ulation run, 2 chains of 1000 posterior samples per chain were generated by the MCMC
algorithm with the first 500 samples per chain as warm-up. We also verified that the
MCMC chains converged well. The posterior means of the generated posterior samples
were used as the point estimates of the unknown parameters for each simulation run. The
mean, empirical standard error (SD) and the mean squared error (MSE) were calculated
based on the 500 point estimates for each unknown parameters.
5.2 Results
The results of the simulation are shown in Table 1 and 2. In Table 1, the mean, SD,
and MSE of the fixed effect and τk estimates were shown. All parameters were estimated
without bias except for τ3 and τ4 that had a relative bias of at most 5 to 10%. Empirical
standard errors for β0, β2, τ1, and τ3 were relatively large and their coverage probabilities
were somewhat conservative (i.e., below the nominal value) but still within the range of
18
simulation (Monte Carlo) variability. In Table 2, the average estimates and the correspond-
ing empirical standard error of the covariance matrix Σ is displayed. In addition, Table 3
shows the mean, SD, and coverage probability of the estimates for the cholesky factor (up-
per triangular matrix) of Σ. Compared to the true value used in the simulation, covariance
estimates related to the after treatment periods (e.g., cov(β0, β2), var(ci)) were underesti-
mated. Even though var(ci) was underestimated, its corresponding scale parameter τ5 was
not. The mean estimate was equal to 0.5469 (τˆ 25 = 0.5469
2 ≈ 0.2991). The bias in the
covariance matrix estimation was introduced due to the underestimation of the parameters
in the correlation matrix, but it did not affect the fixed effects in the longitudinal profile
and the hazard function. Therefore, this approach provides a REML-like estimates of the
fixed effects that are independent of the variance parameters.
6 Case study
The proposed joint model was fitted to the Framingham Heart Study data described in
Section 2. The longitudinal profile considered was the SBP, and the event of interests
was the occurrence of CVD. The objective was to investigate the effect of initiation and
maintenance of anti-hypertensive medication on the SBP profile and the variability of the
SBP, the indirect effect of the treatment on the risk of developing CVD, and the effect of
intra-individual variability on the risk of CVD. Time to CVD event was considered to be
the time of clinical diagnosis. Though an interval-censored survival model would be more
appropriate, the approximation of the true survival time by the diagnosis time at the total
time scale suffice to illustrate the usage of the proposed joint model. Furthermore, a Weibull
baseline distribution was assumed for the survival model based on the recommendation from
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Table 1: Simulation results: mean, empirical standard error (SD), the mean squared error
(MSE), and the coverage probability (CP) of the fixed effect parameters and of the τk in
both the longitudinal and survival model based on 500 simulations.
Point estimate
Parms True value Mean SD MSE CP
Longitudinal model
β0 12 11.9994 0.2037 0.4140 93.8%
β1 0.1 0.1000 0.0084 0.00007 94.4%
β2 -0.3 -0.2858 0.2084 0.0435 95.4%
β3 -0.05 -0.0481 0.0274 0.00008 96.2%
ν 0.5 0.5035 0.0798 0.0064 92.0%
σ0 1.414 1.4166 0.0431 0.0019 95.6%
τ1 2 1.9861 0.1556 0.0243 93.6%
τ2 0.071 0.0722 0.0062 4e-5 95.2%
τ3 1 0.9482 0.2471 0.0636 92.6%
τ4 0.122 0.1382 0.0218 0.0007 92.8%
τ5 0.548 0.5469 0.0462 0.0021 95.6%
Survival model
γ0 0.05 0.0646 0.0537 0.0031 94.6%
γ1 0.2 0.2057 0.3542 0.1252 94.6%
k 1.5 1.5296 0.1192 0.0150 100%
−k log(ξ) -7.516 -7.9345 0.4552 0.3820 100%
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Table 2: Simulation results: mean (and empirical standard error) of the covariance matrix
Ω based on 500 simulations.
b0i b1i b2i b3i ci
b0i 3.9686 (0.6178) -0.0202 (0.0150) -0.1345 (0.2544) -0.0290 (0.0363) 0.5299 (0.1250)
b1i - 0.0052 (0.0009) -0.0051 (0.0100) 0.0024 (0.0012) 0.0088 (0.0043)
b2i - - 0.8941 (0.4413) -0.0073 (0.0177) -0.0578 (0.0765)
b3i - - - 0.01740 (0.0055) -0.0151 (0.0106)
ci - - - - 0.2781 (0.0477)
the literature (Hu, 2013). All posterior estimates of the model generated from the MCMC
algorithm converged well with the split R-hat statistic (potential scale reduction factor)
(Gelman and others , 1992) for all parameters close to 1. Additional graphic inspection
of the trace-plots was also performed. Posterior predictive checking (Gelman and others ,
1996) was performed to assess the goodness-of-fit of the proposed model to the Framingham
Heart Study data and did not indicate lack of fits. (The results of the posterior predictive
checking are provided in Supplementary material).
The results of the estimates of the fixed effect parameters is summarized in Table 4. For
the longitudinal model, it can be seen that the average SBP at baseline was estimated to
be 129 mmHg with an annual natural (without anti-hypertensive medication) growth rate
of 0.74 mmHg/year. The anti-hypertensive medication is estimated to reduce the absolute
value of the SBP by 2.64 mmHg on average and the growth rate by 0.52 mmHg/year. The
main interest, however, lies in the effect of antihypertensive treatment on the variability
of the SBP. This was estimated to be 0.56, which corresponds to a 1.75 ≈ exp(0.56) times
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Table 3: Simulation results: true value, mean (and empirical standard error), coverage
probability of the cholesky factor (upper triangular matrix) of the Ω based on 500 simula-
tions.
b0i b1i b2i b3i ci
True value
b0i 1 -0.1414 -0.1 -0.2041 0.5477
b1i 0 0.9899 -0.2286 0.5541 0.3391
b2i 0 0 0.9684 -0.0589 -0.0519
b3i 0 0 0 0.8049 -0.5613
ci 0 0 0 0 0.5170
Mean (standard error)
b0i 1 -0.1387 (0.0998) -0.0703 (0.1275) -0.1055 (0.1310) 0.4839 (0.0797)
b1i - 0.9792 (0.0156) -0.0758 (0.1350) 0.2289 (0.1151) 0.2913 (0.0911)
b2i - - 0.9380 (0.0224) -0.0358 (0.1190) -0.0531 (0.1119)
b3i - - - 0.8817 (0.0338) -0.2316 (0.1074)
ci - - - - 0.7108 (0.0580)
Coverage probability
b0i - 96.8% 99.0% 97.0% 91.0%
b1i - 98.0% 95.6% 64.4% 93.6%
b2i - - 99.8% 99.8% 99.4%
b3i - - - 98.2% 34.0%
ci - - - - 41.2%
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higher SBP variability after treatment. On the other hand, the parameter estimates in the
survival model indicate that a 10 mmHg increase in the SBP is associated with a hazard
ratio (for CVD) of exp(0.15) ≈ 1.16. Furthermore, 2 times higher SBP standard deviation
is estimated to have a hazard ratio of exp(2 × 0.38 × log 2) ≈ 1.69. Thus, whereas the
use of antihypertensive treatment reduces the risk on CVD through the lowering of SBP,
it may potentially increase the risk of CVD by increasing the variability of SBP. Since the
effect of the change in variability (of SBP) is larger than the effect of the change in SBP,
our results are in line with the finding that patients receiving anti-hypertensive medication
still appear to have higher risk of CVD than those not on anti-hypertensive medication
with the same SBP level (D’Agostino and others , 2008; Psaty and others , 2001; Chambless
and others , 2003, 2004). Furthermore, individuals that will immediately benefit from the
anti-hypertensive medication are those whose subject-specific reduction of the SBP b2i
satisfy the inequality γ0b2i + γ1ν ≤ 0. Since b2i was estimated to have mean −2.640 and
variance 111.41, the percentage of individuals with immediate benefits from the treatment
is approximately Φ((−13.851 + 2.640)/√111.41) ≈ 14.41%.
The estimated correlation matrix (posterior mean) of the five latent variables is pre-
sented in Table 5. A small negative correlation is found between the baseline SBP level (b0i)
and the slope prior to treatment (b1i) which indicates that individuals with higher baseline
SBP experience a slower natural growth rate of SBP. It is however more interesting to see
that the two effects of the treatment, namely the direct lowering effect on the SBP level
(b2i) and the reduction of the growth rate of the SBP (b3i), are all negatively correlated with
the baseline SBP and the growth rate prior to the treatment. Heuristically, this means that
individuals with higher baseline SBP and faster SBP increase before treatment are more
likely to benefit from the anti-hypertensive medication either by a direct SBP lowering
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Table 4: Fixed effect parameter estimates of the joint model fitted to the Framingham
Heart Study data
Parms
Posterior
Mean (SD)
MCSE 95% Quantile Interval
Longitudinal model
β0
128.963
(0.297)
0.016 128.371 129.530
β1
0.741
(0.014)
0.0004 0.714 0.768
β2
-2.640
(0.448)
0.011 -3.53 -1.758
β3
-0.516
(0.049)
0.002 -0.615 -0.421
ν
0.5567
(0.0215)
0.0005 0.5425 0.5988
σ0
11.524
(0.065)
0.002 11.397 11.652
Survial model
γ0
0.01539
(0.00062)
0.00001 0.0141 0.0165
γ1
0.3829
(0.0494)
0.0011 0.2858 0.4167
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and/or by a larger reduction in the progression after treatment. Furthermore, the correla-
tion between SBP variability and SBP level as mentioned in Section 1, is captured by the
large positive correlation between b0i and ci in Table 5. Not surprisingly, a higher SBP level
is associated with a higher variability and the SBP variability is positively correlated with
the growth rate. However, more strikingly, both treatment effects are negatively correlated
with the SBP variability, indicating that the anti-hypertensive medication is more benefi-
cial for individuals with a higher SBP variability. Since higher variability corresponds to
higher SBP levels and faster progression before treatment, this finding is consistent with
the previously presented findings.
Table 5: Estimated correlation matrix of the random effect of the joint model fitted to
the Framingham Heart Study data
b0i b1i b2i b3i ci
b0i 1.000 -0.1763 -0.0986 -0.2360 0.6285
b1i -0.1763 0.9991 -0.2782 -0.5728 0.2691
b2i -0.0986 -0.2782 0.9945 -0.1319 -0.1241
b3i -0.2360 -0.5728 -0.1319 0.9926 -0.3713
ci 0.6285 0.2691 -0.1241 -0.3713 0.9954
7 Discussion
In this investigation, we have formulated an innovative joint model for longitudinal risk
factor profiles and survival outcome was proposed. It incorporates direct modeling of the
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intra-individual variability of the longitudinal profile in both the longitudinal and survival
model and it handles the impact of disruptive patterns in the longitudinal profile of the
putative risk factor. This model provides opportunities to investigate the effect of treatment
on both the longitudinal profile of a given risk factor and its residual variance, and relate
these changes to the risk of outcome events on follow-up. Simulation results showed that the
proposed method was able to estimate all fixed effect parameters in both the longitudinal
and survival model (almost) without bias. To obtain numerical stability, we decomposed
the variance-covariance matrix of all random effects into a scale and a correlation matrix
and further decomposed the correlation matrix using Cholesky decomposition. However, for
100 individuals per simulation, sample size was not sufficient to guarantee the convergence
to the true values of the parameters in the corelation matrix. A possible improvement is the
use of Fisher’s z transformation on the correlation parameters to make the distribution of
the estimates closer to a normal distribution at lower numbers of individuals. Nevertheless,
for the analysis of the Framingham Heart Study this transformation was not needed due to
much larger sample size. In the analysis of the Framingham Heart Study using the proposed
joint model, we were able to identify the pros and cons of the anti-hypertensive medication.
It reduced the absolute value of the SBP and decreases its progression but at the expense of
a higher SBP variability. Since our model demonstrated that higher variability is associated
with elevated risk of developing CVD, the beneficial effects of treatment on lowering SBP
may be partly or possibly fully offset by an increase in variability, a premise worthy of
investigating in the future.
It should be noted that the parameters in the treatment allocation model were not
discussed in the present investigation since the treatment allocation model factorizes the
likelihood function and it can be ignored. However, it is straightforward to incorporate the
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treatment allocation model by considering the complete likelihood function instead of the
partial likelihood function.
Though a Bayesian framework is adopted, other estimation methods such as the expec-
tation maximization (EM) algorithm and its variations, for instance Monte Carlo EM (Wei
and Tanner, 1990) and PX-EM (Liu and others , 1998), would also be possible. Further-
more, the proposed joint model is flexible in the way that the modeling of the longitudinal
profile and survival outcome together with the modeling of the longitudinal profile vari-
ability can include additional covariates to reflect the domain-specific knowledge of the
phenomenon that one tries to investigate. For instance, in the Framingham Heart Study or
other studies of CVD, intervenable risk factors such as smoking behavior of the individual
and its effect on both the blood pressure profile and the risk of developing CVD may be of
interests to the investigators. Then inclusion of this additional time-dependent covariate
similar to the time-dependent treatment in the current joint model may be introduced.
Finally, in the current joint model the association between the longitudinal profile and
the survival outcome is linked directly via the time-dependent conditional mean and vari-
ance of the longitudinal profile. However, one may wish to adopt the shared latent variable
joint model framework, which uses the latent variables θ themselves in the survival model.
This may be of interests for future studies as well.
8 Software
Simulation code (SAS) and the implemented code for the proposed model (Stan), together
with the R scripts that generate the results presented in this article are available on https:
//github.com/jujae/hetJM/.
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9 Supplementary Material
1000 New observations yrep was drawn from the posterior predictive distribution of the
longitudinal profile y per observation in the Framingham Heart Study data set.
Figure 4: Kernel density estimates of yrep overlaid with the distribution of y itself (The
scale is 1/10 of the original SBP)
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